Literature DB >> 36184717

Probing Alterations in MDM2 Catalytic Core Structure Effect of Garcinia Mangostana Derivatives: Insight from Molecular Dynamics Simulations.

Aisha I El Habbash1, Aimen Aljoundi1, Ghazi Elamin1, Mahmoud E S Soliman2.   

Abstract

The MDM2-p53 protein-protein interaction is a promising model for researchers to design, study, and discover new anticancer drugs. The design of therapeutically active compounds that can maintain or restore the binding of MDM2 to p53 has been found to limit the oncogenic activities of both. This led to the current development of a group of xanthone-core and cis-imidazoline analogs compounds, among which γ-Mangostin (GM), α-Mangostin (AM), and Nutlin exhibited their MDM2-p53 interaction inhibitory effects. Therefore, in this study, we seek to determine the mechanisms by which these compounds elicit MDM2-p53 interaction targeting. Unique to the binding of GM, AM, and Nutlin, from our findings, they share the same three active site residues Val76, Tyr50, and Gly41, which represent the top active side residues that contribute to high electrostatic energy. Consequently, the free binding energy contributed enormously to the binding of these compounds, which culminated in the high binding affinities of GM, AM, and Nutlin with high values. Furthermore, GM, AM, and Nutlin commonly interrupted the stable and compact conformation of MDM2 coupled with its active site, where Cα deviations were relatively high. We believe that our findings would assist in the design of more potent active anticancer drugs.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  MDM2–p53; Molecular dynamic simulation; Nutlin; α-Mangostin (AM); γ-Mangostin (GM)

Mesh:

Substances:

Year:  2022        PMID: 36184717     DOI: 10.1007/s12013-022-01101-4

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.989


  43 in total

Review 1.  Live or let die: the cell's response to p53.

Authors:  Karen H Vousden; Xin Lu
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

2.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

3.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

Review 4.  Mutational spectrum of p53 mutations in primary breast and ovarian tumors.

Authors:  Anis Feki; Irmgard Irminger-Finger
Journal:  Crit Rev Oncol Hematol       Date:  2004-11       Impact factor: 6.312

Review 5.  MDM2--master regulator of the p53 tumor suppressor protein.

Authors:  J Momand; H H Wu; G Dasgupta
Journal:  Gene       Date:  2000-01-25       Impact factor: 3.688

Review 6.  Control of apoptosis by p53.

Authors:  Jordan S Fridman; Scott W Lowe
Journal:  Oncogene       Date:  2003-12-08       Impact factor: 9.867

Review 7.  Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome.

Authors:  Jose G Teodoro; Sara K Evans; Michael R Green
Journal:  J Mol Med (Berl)       Date:  2007-06-23       Impact factor: 4.599

Review 8.  The MDM2 gene amplification database.

Authors:  J Momand; D Jung; S Wilczynski; J Niland
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

Review 9.  Targeting apoptosis pathways for new cancer therapeutics.

Authors:  Longchuan Bai; Shaomeng Wang
Journal:  Annu Rev Med       Date:  2013-11-04       Impact factor: 13.739

10.  Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

Authors:  S S Fakharzadeh; S P Trusko; D L George
Journal:  EMBO J       Date:  1991-06       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.